Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Allergens are typically foreign proteins or glycoproteins that elicit an immune response by binding to immunoglobulin E (IgE) antibodies in humans. This IgE-mediated recognition is central to the development of allergic diseases. They contain B-cell epitopes that bind to IgE and T-cell epitopes that induce a Th2 response. Upon re-exposure, allergens cross-link surface-bound IgE on mast cells/basophils, triggering degranulation and release of inflammatory mediators, leading to allergic symptoms. Therapeutic targeting includes avoidance, pharmacologic suppression, and immunotherapy.
Antihistamines: H1 receptor antagonist; Corticosteroids: Anti-inflammatory; Epinephrine: Adrenergic receptor agonist; Omalizumab: Binds to IgE, preventing binding to FcεRI; Allergen immunotherapy: Induces tolerance to allergen
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Allergen (IgE-binding protein).